Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026
Benzinga Newsdesk 4 weeks ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be presented as a poster presentation at Obesity Week® 2026, taking place from November 14–17, 2026 in National Harbor, MD.
